ISAL 2019 | Clonal interference of signaling mutations in AML: impacts on outcome
Raphael Itzykson
• 25 Feb 2019
Raphael Itzykson, MD, PhD, of Hôpital Saint-Louis, Paris, France, discusses the clonal interference of signaling mutations in acute myeloid leukemia (AML). His group identified a subset of CBF-AML patients that harbor several signaling gene mutations, which arose in independent clones. Prof. Itzykson discusses the impacts of this clonal interference on long-term outcomes, and further research planned in this area. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
